By Scientia Professor Vlado Perkovic

Journal articles

Liyanage T; Ninomiya T; Perkovic V; Woodward M; Stirnadel-Farrant H; Matsushita K; Iseki K; Seong HL; Monaghan H; Jha V, 2017, 'Chronic kidney disease in Asia: Protocol for a collaborative overview', Nephrology, 22, pp. 456 - 462, http://dx.doi.org/10.1111/nep.12821

Jun M; James MT; Ma Z; Zhang J; Tonelli M; McAlister FA; Manns BJ; Ravani P; Quinn RR; Wiebe N; Perkovic V; Wilton SB; Winkelmayer WC; Hemmelgarn BR, 2017, 'Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation', American Journal of Kidney Diseases, 69, pp. 734 - 743, http://dx.doi.org/10.1053/j.ajkd.2016.10.018

Perkovic V; Levin A; Wheeler D; Koitka-Weber A; Mattheus M; George J; von Eynatten M; Wanner C, 2017, 'SO019EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', Nephrology Dialysis Transplantation, 32, pp. iii12 - iii12, http://dx.doi.org/10.1093/ndt/gfx103

Wanner C; Levin A; Perkovic V; Koitka-Weber A; Mattheus M; von Eynatten M; Wheeler D, 2017, 'SP259EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', Nephrology Dialysis Transplantation, 32, pp. iii193 - iii194, http://dx.doi.org/10.1093/ndt/gfx145.sp259

Pena MJ; de Zeeuw D; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Kohan DE; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; Sharma S; Corringham T; Sharma K; Heerspink HJL, 2017, 'The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy', Diabetes, Obesity and Metabolism, 19, pp. 749 - 753, http://dx.doi.org/10.1111/dom.12864

Heerspink HJL; Makino H; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Davis JW; Idler K; Kohan DE; Liu M; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D, 2017, 'Comparison of exposure response relationship of atrasentan between North American and Asian populations', Diabetes, Obesity and Metabolism, 19, pp. 545 - 552, http://dx.doi.org/10.1111/dom.12851

Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D, 2017, 'Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS-R): A randomized, placebo-controlled trial', Diabetes, Obesity and Metabolism, 19, pp. 387 - 393, http://dx.doi.org/10.1111/dom.12829

Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S, 2017, 'Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients', Cochrane Database of Systematic Reviews, 2017, http://dx.doi.org/10.1002/14651858.CD009966.pub2

Heerspink HJL; Desai M; Jardine M; Balis D; Meininger G; Perkovic V, 2017, 'Canagliflozin slows progression of renal function decline independently of glycemic effects', Journal of the American Society of Nephrology, 28, pp. 368 - 375, http://dx.doi.org/10.1681/ASN.2016030278

Neuen BL; Chadban SJ; Demaio AR; Johnson DW; Perkovic V, 2017, 'Chronic kidney disease and the global NCDs agenda', BMJ Global Health, 2, http://dx.doi.org/10.1136/bmjgh-2017-000380

Su X; Xie X; Liu L; Lv J; Song F; Perkovic V; Zhang H, 2017, 'Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis', American Journal of Kidney Diseases, 69, pp. 69 - 77, http://dx.doi.org/10.1053/j.ajkd.2016.07.033

Atkins ER; Hirakawa Y; Salam A; Woodward M; Cooper M; Hamet P; Harrap S; Lees K; Liu L; Mancia G; Marre M; Perkovic V; Poulter N; Williams B; Chalmers J; Rodgers A, 2017, 'Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: An analysis of the PROGRESS and ADVANCEtrials', Journal of Hypertension, 35, pp. 1318 - 1325, http://dx.doi.org/10.1097/HJH.0000000000001287

Perkovic V, 2016, 'Commentary', Annals of Internal Medicine, 165, pp. JC71, http://dx.doi.org/10.7326/ACPJC-2016-165-12-071

Perkovic V; Agarwal R; Fioretto P; Hemmelgarn BR; Levin A; Thomas MC; Wanner C; Kasiske BL; Wheeler DC; Groop PH; Bakris GL; Cooper ME; Chae DW; Davidson MH; de Boer IH; de Zeeuw D; Fornoni A; Gnudi L; Herzog CA; Hung AM; Jafar TH; Jardine M; Jha V; Ji L; Kahn SE; Langham RG; Lerma EV; Ma RCW; Makino H; Marre M; Mauer M; Metsärinne K; Nelson RG; Pecoits-Filho R; Pollock CA; Rajapurkar M; Rossing P; Rychlík I; Sharma K; Stanton RC; Tesař V; Tikkanen I; Tomson CRV; Toto RD; Tsukamoto Y; Tuttle KR; Wada T; Williams WW; Zhang H; Zoungas S, 2016, 'Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference', Kidney International, 90, pp. 1175 - 1183, http://dx.doi.org/10.1016/j.kint.2016.09.010

Olsen MH; Angell SY; Asma S; Boutouyrie P; Burger D; Chirinos JA; Damasceno A; Delles C; Gimenez-Roqueplo AP; Hering D; López-Jaramillo P; Martinez F; Perkovic V; Rietzschel ER; Schillaci G; Schutte AE; Scuteri A; Sharman JE; Wachtell K; Wang JG, 2016, 'A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension', The Lancet, 388, pp. 2665 - 2712, http://dx.doi.org/10.1016/S0140-6736(16)31134-5

Wong MG; Perkovic V, 2016, 'Knowing what we do not know: statin therapy in advanced chronic kidney disease', The Lancet Diabetes and Endocrinology, 4, pp. 801 - 803, http://dx.doi.org/10.1016/S2213-8587(16)30192-9

Quach K; Lvtvyn L; Baigent C; Bueti J; Garg AX; Hawley C; Haynes R; Manns B; Perkovic V; Rabbat CG; Wald R; Walsh M, 2016, 'The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis', American Journal of Kidney Diseases, 68, pp. 591 - 598, http://dx.doi.org/10.1053/j.ajkd.2016.04.011

Badve SV; Palmer SC; Strippoli GFM; Roberts MA; Teixeira-Pinto A; Boudville N; Cass A; Hawley CM; Hiremath SS; Pascoe EM; Perkovic V; Whalley GA; Craig JC; Johnson DW, 2016, 'The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis', American Journal of Kidney Diseases, 68, pp. 554 - 563, http://dx.doi.org/10.1053/j.ajkd.2016.03.418

Patel MR; Armstrong PW; Bhatt DL; Braunwald E; Camm AJ; Fox KAA; Harrington RA; Hiatt WR; James SK; Kirtane AJ; Leon MB; Lincoff AM; Mahaffey KW; Mauri L; Mehran R; Mehta SR; Montalescot G; Nicholls SJ; Perkovic V; Peterson ED; Pocock SJ; Roe MT; Sabatine MS; Sekeres M; Solomon SD; Steg G; Stone GW; Van De Werf F; Wallentin L; White HD; Gibson CM, 2016, 'Sharing data from cardiovascular clinical trials \- a proposal', New England Journal of Medicine, 375, pp. 407 - 409, http://dx.doi.org/10.1056/NEJMp1605260

Liyanage T; Ninomiya T; Wang A; Neal B; Jun M; Wong MG; Jardine M; Hillis GS; Perkovic V; Jun M; Wang Y, 2016, 'Effects of the mediterranean diet on cardiovascular outcomes-a systematic review and meta-analysis', PLoS ONE, 11, pp. e0159252, http://dx.doi.org/10.1371/journal.pone.0159252

Gabb GM; Mangoni A; Anderson CS; Cowley D; Dowden JS; Golledge J; Hankey GJ; Howes FS; Leckie L; Perkovic V; Schlaich M; Zwar NA; Medley TL; Arnolda L, 2016, 'Guideline for the diagnosis and management of hypertension in adults — 2016', Medical Journal of Australia, 205, pp. 85 - 89, http://dx.doi.org/10.5694/mja16.00526

Chan KE; Giugliano RP; Patel MR; Abramson S; Jardine M; Zhao S; Perkovic V; Maddux FW; Piccini JP, 2016, 'Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF', Journal of the American College of Cardiology, 67, pp. 2888 - 2899, http://dx.doi.org/10.1016/j.jacc.2016.02.082

Rodgers A; Perkovic V, 2016, 'A randomized trial of intensive versus standard blood-pressure control [10]', New England Journal of Medicine, 374, pp. 2295, http://dx.doi.org/10.1056/NEJMc1602668

Roberts MA; Pilmore HL; Ierino FL; Badve SV; Cass A; Garg AX; Isbel NM; Krum H; Pascoe EM; Perkovic V; Scaria A; Tonkin AM; Vergara LA; Hawley CM; Levin A; Hare D; Martin A; Wheeler DC; Fulcher G; Brown H; Colquhoun D; Korczyk D; Mather A; Wong A; Bisscheroux P; Gillies A; Garvey L; Tan KS; Lennan E; Pitkin M; Ahearn K; Carroll RP; Scott E; Cooper B; Pearse J; Snelling P; Burman J; Hand S; Pedagogos E; Karschimkus C; Pilmore A; Walker R; Ellis G; Marshall MR; Paul C; Johnson D; Helyar J; Morrish A; Paul-Brent PA; Reidlinger D; Zhang L, 2016, 'The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) feasibility study: A randomized controlled trial', American Journal of Kidney Diseases, 67, pp. 902 - 911, http://dx.doi.org/10.1053/j.ajkd.2015.10.029

Nigwekar SU; Kang A; Zoungas S; Cass A; Gallagher MP; Kulshrestha S; Navaneethan SD; Perkovic V; Strippoli GFM; Jardine MJ, 2016, 'Interventions for lowering plasma homocysteine levels in dialysis patients', Cochrane Database of Systematic Reviews, 2016, http://dx.doi.org/10.1002/14651858.CD004683.pub4

Wu JHY; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B, 2016, 'Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis', The Lancet Diabetes and Endocrinology, 4, pp. 411 - 419, http://dx.doi.org/10.1016/S2213-8587(16)00052-8

Wong MG; Perkovic V; Chalmers J; Woodward M; Li Q; Cooper ME; Hamet P; Harrap S; Heller S; Macmahon S; Mancia G; Marre M; Matthews D; Neal B; Poulter N; Rodgers A; Williams B; Zoungas S, 2016, 'Long-term benefits of intensive glucose Control for preventing end-stage kidney disease: ADVANCE-ON', Diabetes Care, 39, pp. 694 - 700, http://dx.doi.org/10.2337/dc15-2322

Schievink B; De Zeeuw D; Smink PA; Andress D; Brennan JJ; Coll B; Correa-Rotter R; Hou FF; Kohan D; Kitzman DW; Makino H; Parving HH; Perkovic V; Remuzzi G; Tobe S; Toto R; Hoekman J; Lambers Heerspink HJ, 2016, 'Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers', European Journal of Preventive Cardiology, 23, pp. 758 - 768, http://dx.doi.org/10.1177/2047487315598709

Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H, 2016, 'Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials', American Journal of Kidney Diseases, 67, pp. 728 - 741, http://dx.doi.org/10.1053/j.ajkd.2015.10.011

Wang Y; Ivany JN; Perkovic V; Gallagher MP; Woodward M; Jardine MJ, 2016, 'Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease', Cochrane Database of Systematic Reviews, 2016, http://dx.doi.org/10.1002/14651858.CD009631.pub2

Gallagher M; Wong MG; Perkovic V, 2016, 'ALTITUDE: Defining a ceiling for blockade of the renin-angiotensin system?', The Lancet Diabetes and Endocrinology, 4, pp. 289 - 290, http://dx.doi.org/10.1016/S2213-8587(15)00518-5

Knight J; Perkovic V, 2016, 'The Affordable Dialysis Prize steams ahead', The Lancet, 387, pp. 1040, http://dx.doi.org/10.1016/S0140-6736(16)00657-7

Dal-Ré R; Jha V; Lv J; Chaudhury RR; Wang Y; Perkovic V, 2016, 'International trials in middle-income countries: different local scenarios require different ethical approaches', Journal of the Royal Society of Medicine, 109, pp. 47 - 51, http://dx.doi.org/10.1177/0141076815608854

Xie X; Atkins E; Lv J; Bennett A; Neal B; Ninomiya T; Woodward M; MacMahon S; Turnbull F; Hillis GS; Chalmers J; Mant J; Salam A; Rahimi K; Perkovic V; Rodgers A, 2016, 'Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis', The Lancet, 387, pp. 435 - 443, http://dx.doi.org/10.1016/S0140-6736(15)00805-3

Zhang L; Coombes J; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW, 2016, 'The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial', Redox Report, 21, pp. 14 - 23, http://dx.doi.org/10.1179/1351000215Y.0000000022

Sukkar L; Hong D; Wong MG; Badve SV; Rogers K; Perkovic V; Walsh M; Yu X; Hillis GS; Gallagher M; Jardine M, 2016, 'Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: Systematic review and meta-analysis', BMJ (Online), 355, http://dx.doi.org/10.1136/bmj.i5599

Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Mathieu C; Woo V; Wysham C; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B; Home P; Anderson J; Campbell I; Lachin J; Scharfstein D; Solomon S; Uzzo R; Amerena J; Chow C; Figtree G; French G; Hillis J; Jenkins B; Lindley R; McGrath B; Street A; Watson J, 2016, 'Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes', Diabetes, Obesity and Metabolism, 18, pp. 82 - 91, http://dx.doi.org/10.1111/dom.12589

Sukkar L; Hong D; Wong MG; Badve SV; Perkovic V; Yu X; Hillis GS; Gallagher M; Jardine M, 2016, 'MP221EFFECTS OF ISCHAEMIC CONDITIONING ON MAJOR CLINICAL OUTCOMES IN PEOPLE UNDERGOING INVASIVE PROCEDURES: A SYSTEMATIC REVIEW AND METAANALYSIS', Nephrology Dialysis Transplantation, 31, pp. i413 - i413, http://dx.doi.org/10.1093/ndt/gfw187.27

Anderson C; Arnolda L; Cowley D; Dowden J; Gabb G; Golledge J; Hankey G; Howes F; Leckie L; Mangoni A; Perkovic V; Schlaich M; Zwar N; Medley T; Wilson J; Branagan M, 2016, 'National Heart Foundation Hypertension Guideline - 2016', Heart, Lung and Circulation, 25, pp. S18 - S18, http://dx.doi.org/10.1016/j.hlc.2016.06.039

Perkovic V; Rodgers A, 2015, 'Redefining blood-pressure targets - SPRINT starts the marathon', New England Journal of Medicine, 373, pp. 2175 - 2178, http://dx.doi.org/10.1056/NEJMe1513301

Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; Von Eynatten M, 2015, 'Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D^™ trial', Diabetes and Vascular Disease Research, 12, pp. 455 - 462, http://dx.doi.org/10.1177/1479164115579002

Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GFM, 2015, 'HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis', Sao Paulo Medical Journal, 133, pp. 541, http://dx.doi.org/10.1590/1516-3180.20151336T2

Perkovic V; Jardine M; Vijapurkar U; Meininger G, 2015, 'Renal effects of canagliflozin in type 2 diabetes mellitus', Current Medical Research and Opinion, 31, pp. 2219 - 2231, http://dx.doi.org/10.1185/03007995.2015.1092128

Thomas MC; Woodward M; Neal B; Li Q; Pickering R; Marre M; Williams B; Perkovic V; Cooper ME; Zoungas S; Chalmers J; Hillis GS, 2015, 'Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes', Diabetes Care, 38, pp. 1891 - 1897, http://dx.doi.org/10.2337/dc15-0925

Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Weiss R; Rosenstock J; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B, 2015, 'Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial', Diabetes Therapy, 6, pp. 289 - 302, http://dx.doi.org/10.1007/s13300-015-0117-z

Toyama T; Furuichi K; Shimizu M; Hara A; Iwata Y; Sakai N; Perkovic V; Kobayashi M; Mano T; Kaneko S; Wada T, 2015, 'Relationship between serum uric acid levels and chronic kidney disease in a Japanese cohort with normal or mildly reduced kidney function', PLoS ONE, 10, http://dx.doi.org/10.1371/journal.pone.0137449

Kohan DE; Heerspink HJL; Coll B; Andress D; Brennan JJ; Kitzman DW; Correa-Rotter R; Makino H; Perkovic V; Hou FF; Remuzzi G; Tobe SW; Toto R; Parving HH; De Zeeuw D, 2015, 'Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy', Clinical Journal of the American Society of Nephrology, 10, pp. 1568 - 1574, http://dx.doi.org/10.2215/CJN.00570115

Jun M; Turin TC; Woodward M; Perkovic V; Lambers Heerspink HJ; Manns BJ; Tonelli M; Hemmelgarn BR, 2015, 'Assessing the validity of surrogate outcomes for ESRD: A meta-analysis', Journal of the American Society of Nephrology, 26, pp. 2289 - 2302, http://dx.doi.org/10.1681/ASN.2014040396

Jardine M; Perkovic V, 2015, 'First Light after the Long Night: A Follow-up Report of the Randomized FHN Nocturnal Trial', American Journal of Kidney Diseases, 66, pp. 379 - 382, http://dx.doi.org/10.1053/j.ajkd.2015.06.007

Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; Von Eynatten M, 2015, 'Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data from a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes', American Journal of Kidney Diseases, 66, pp. 441 - 449, http://dx.doi.org/10.1053/j.ajkd.2015.03.024

Back to profile page